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Background: Uterine leiomyosarcomas (LMSs) are rare and aggressive but difﬁcult to predict before
surgery. Minimally invasive surgery using morcellation might cause tumor spreading during manipu-
lating of tumor tissue. We aim to study the inﬂuence of morcellation on the prognosis of patients with
early uterine LMS.
Methods: We retrospectively reviewed the medical records of all patients with stage 1 LMS treated
between April 1993 and April 2014. Demographics and outcomes were compared between patients who
underwent total hysterectomy without morcellation and those who underwent surgery with abdominal,
vaginal, and laparoscopic morcellation.
Results: In total, 43 consecutive patients were identiﬁed, including 29 without morcellation and 14 with
morcellation. Tumor size was signiﬁcantly smaller (7.3 cm vs. 11.6 cm, p ¼ 0.006) in patients with
morcellation. Six (42.9%) patients with morcellation received reoperation at 18.5 days after the initial
surgery. Patients with morcellation did not show higher recurrence rate, including the recurrence rate at
the pelvic cavity, compared with patients without morcellation. Compared with patients without mor-
cellation, KaplaneMeier curves did not show signiﬁcant difference in the disease-free survival (DFS) and
overall survival (OS) in patients with morcellation. In univariate and multivariate analyses, tumor size
was signiﬁcantly associated with poor DFS and OS. Morcellation was not associated with survivals.
Conclusion: In patients with stage 1 LMS, survival is associated with tumor size. Morcellation does not
seem to be associated with a worse prognosis in early stage LMS.
Copyright © 2015, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Uterine leiomyosarcoma (LMS) is a rare disease with an annual
incidence of 0.4e0.64/100,000 women1,2 and accounts for 1e2% of
uterine cancer cases.3 It is a highly aggressive tumor with high
recurrence rates, and complete surgical resection is the only
established curative treatment.4 However, there is no available
imaging technique to accurately diagnose LMS arising frommyoma
before the operation.5,6 Consequently, LMS are usually under-
diagnosed and treated by myomectomy or minimally invasive
surgeries.e no conﬂicts of interest.
s and Gynecology, National
South Road, Taipei 10002,
for Gynecologic Endoscopy and MinimHysteroscopic or laparoscopic myomectomies or hysterectomies
using morcellator knife might cause disruption of LMS during
surgery. Tumor tissue spreading during surgery is associated with
high tumor recurrence rates and poor patient outcomes.7e9 Apart
from morcellation, several other factors could inﬂuence the sur-
vival outcome of patients with LMS.10 The aim of this study is to
evaluate the inﬂuence of the initial surgical procedures on the
survival outcome of patients with early localized stage 1 LMS.
Literature review of recurrence rate and survival outcome of early
LMS is also presented.
Materials and methods
Patients
This study was conducted with approval from the Institutional
Review Board at the National Taiwan University College ofally Invasive Therapy. Published by Elsevier Taiwan LLC. All rights reserved.
Table 2
Surgical treatment, adjuvant management, and survival outcome.
Nonmorcellation
group (n ¼ 29)
Morcellation
group
(n ¼ 14)
p
Procedure performed at initial operation
Total abdominal hysterectomy 28 0
Bilateral salpingo-oophorectomy 23 3
Pelvic lymph node dissection 6 0
Vaginal total hysterectomy 1 0
Laparoscopic-assisted vaginal
hysterectomy
0 8
Myomectomy 0 2
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uterine LMS operated in our institute between April 1993 and April
2014 were included retrospectively. Demographic and clinical data
were collected from medical records and pathological reports
including patient age, parity, operative procedure, size of tumor,
mitotic counts, timing, and postoperative adjuvant therapy. Follow-
up data including tumor recurrence, anatomical location of tumor
recurrence, and patient outcomewere recorded. Pathological slides
were reviewed by two experienced pathologists. Patients were
divided into two groups, namely, those who underwent total hys-
terectomy without morcellation and those who underwent surgery
with abdominal, vaginal, and laparoscopic morcellation.
Statistical analysis
Parametric continuous variables were compared using a t test
for independent samples. Nonparametric dichotomous variables
were compared using Chi-square or Fisher's exact tests. Survival
time was recorded from the date of operation to the date of death
from disease or the date of censor. KaplaneMeier analysis with a
log-ranking test was used to estimate survival probabilities and
compare survival distributions stratiﬁed by operative procedures
with or without morcellation. Univariate and multivariate regres-
sion analyses based on a Cox proportional hazard model were used
to evaluate the relative importance of variables as predictors of
survival time. The statistical analysis was carried out using SAS
version 8.0 (SAS Institute, Cary, NC, USA). A p value < 0.05 was
considered signiﬁcant.
Literature review
Articles on uterine LMS published in English from 1989 to 2014
were identiﬁed systematically by computer-based searches in
MEDLINE and the Cochrane Library. Only cases with International
Federation of Gynecology and Obstetrics (FIGO) stage 1e2 were
included. Tumor size, recurrence rate, locoregional recurrence rate,
and survival outcome were tabulated.
Results
A total of 43 patients with stage 1 LMS were identiﬁed during
the study period. Demographic and clinical variables of the two
groups of patients are presented in Table 1. Therewere no between-
group differences in age, parity, lymph node dissection, ovarian
preservation, and mitotic count. Patients in the morcellation group
had signiﬁcantly smaller tumors than patients in theTable 1
Demographic and clinical variables (n ¼ 43).
Nonmorcellation
group (n ¼ 29)
Morcellation
group (n ¼ 14)
p
Age (y) 53.7 ± 10.4 49.7 ± 6.2 0.19
Parity 1.9 ± 1.4 1.6 ± 1.3 0.51
Size (cm) 11.6 ± 4.9
(4e21)
7.3 ± 2.9
(3e13)
0.006
Lymph node dissection 7 (24.1) 5 (35.7) 0.48
Ovarian preservation 6 (20.7) 6 (42.9) 0.16
Mitotic count
Low (< 10/10 HPF) 6 2
High ( 10/10 HPF) 19 7 1.0
Reoperation 1 (3.4) 6 (42.9) 0.003
Period between initial
operation &
reoperation (d)
16 18.5 ± 20.6
(7e60)
Data are presented as n (%) or mean ± SD.
HPF ¼ high power ﬁeld.nonmorcellation group. One patient in the nonmorcellation group
received lymph node dissection (staging surgery) 16 days after the
initial surgery. All six patients who received myomectomy (by
abdominal, laparoscopic, or hysteroscopic approaches) in the
morcellation group were reoperated at 7e60 days after the initial
surgery.
Surgical and adjuvant managements and patient outcomes are
presented in Table 2. Seven patients in the nonmorcellation group
and four patients in the morcellation group completed the staging
procedure. None of the patients was upstaged after the staging
surgery. There were no differences in postoperative adjuvant
therapy such as radiotherapy and chemotherapy between the two
groups. After a median and mean follow-up of 20 months and 55
(range, 1e245) months for the nonmorcellation group, and 24
months and 33 (range, 12e99) months for the morcellation group,
respectively, tumor recurred in 14 patients (48.2%) in the non-
morcellation group and in eight (57.1%) in the morcellation group.
Pelvic recurrence occurred in four (14%) patients in the non-
morcellation group and in three (21%) patients in the morcellation
group. No signiﬁcant differences were found between these two
groups in recurrence rates, location of recurrence, and patient
outcomes at the time of analysis. Table 3 presents the recurrence
rates and sizes of tumor according to different surgical approaches.
Higher tumor recurrence rate was associated with greater tumor
size only in patients without morcellation.
The 3-year overall survival (OS) rate was 39.2% for all patients,
52.4% for patients in the nonmorcellation group, and 33.7% for
patients in themorcellation group. The 5-year OS ratewas 34.3% for
all patients, 34.0% for patients in the nonmorcellation group, and
33.7% for patients in the morcellation group. In Cox proportional
regression analysis for disease-free survival (DFS) and OS, tumor
size was the only variable that signiﬁcantly inﬂuenced survival. In
multivariate analyses, the hazard ratios of tumor morcellationwereLaparoscopic myomectomy 0 2
Hysteroscopic myomectomy 0 2
Procedure performed at reoperation
Total abdominal hysterectomy 0 6
Bilateral salpingo-oophorectomy 0 5
Pelvic lymph node dissection 1 4
Adjuvant therapy 0.15
None 15 (51.7) 3 (21.4)
Radiotherapy 9 (31.0) 6 (42.9)
Chemotherapy 5 (17.2) 5 (33.7)
Recurrence 0.83
No 15 (51.7) 6 (42.9)
Yes 14 (48.3) 8 (57.1)
Recurrence location 0.30
Abdomen/pelvis 2 (14.3) 3 (37.5)
Other 10 (71.4) 5 (62.5)
Both 2 (14.3) 0 (0)
Outcome 0.79
Alive 15 (51.7) 6 (42.9)
Alive with disease 1 (3.4) 1 (7.1)
dead 13 (44.8) 7 (50.0)
Data are presented as n (%).
Table 3
Tumor recurrence and tumor sizes in different surgical techniques.
Total case Recurrences Tumor size without recurrence (cm) Tumor size with recurrence (cm) p
Myomectomy via laparotomy 2 1 (50.0) 11 7
Hysteroscopic myomectomy 2 1 (50.0) 4.5 4
Laparoscopic myomectomy with morcellator 2 0 (0) 6.8 ± 4.0 (4e9.6) d
Laparoscopic hysterectomy 8 6 (75.0) 9.5 ± 5.0 (6e13) 7.05 ± 2.03 (3e8.3) 0.32
Total vaginal hysterectomy 1 0 (0) 4.5 d
Total/subtotal abdominal hysterectomy 28 14 (50.0) 9.63 ± 3.54 (4.5e17) 14.0 ± 5.0 (4.5e21) 0.01
Data are presented as n (%) or mean ± SD (range).
Table 4
Survival analysis in patients with early LMS.
Variables Univariate analysis Multivariate analysis
Disease-free survival Overall survival Disease-free survival Overall survival
HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Age (y) 1.05 (1.00e1.10) 0.08 1.05 (1.00e1.11) 0.07 1.03 (0.98e1.08) 0.26 1.04 (0.99e1.09) 0.16
Morcellation (yes vs. no) 1.01 (0.42e2.42) 0.99 1.10 (0.44e2.78) 0.84 2.16 (0.69e6.75) 0.19 2.31 (0.73e7.34) 0.15
Size of tumor (cm) 1.18 (1.05e1.33) 0.005 1.14 (1.02e1.28) 0.02 1.20 (1.05e1.38) 0.01 1.15 (1.01e1.32) 0.04
Mitotic count
(high vs. low)
5.74 (0.76e43.6) 0.09 5.75 (0.75e43.94) 0.09 5.04 (0.65e39.26) 0.12 4.72 (0.60e37.31) 0.14
CI ¼ conﬁdence interval; HR ¼ hazard ratio; LMS ¼ leiomyosarcoma.
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was not an independent prognostic factor associated with patient
survivals (Table 4). Figures 1 and 2 show the DFS and OS relative to
tumor morcellation in patients with stage 1 LMS.
Table 5 lists the literature reports of tumor size, recurrence rate,
pelvic recurrence rate, and survival outcome for early stage LMS
with or without using morcellation. Figure 3 shows the survival
outcome in patients with early stage LMS without using morcel-
lation based on literature reports listed in Table 5.
Discussion
Six studies have assessed the impact of tumor morcellation on
tumor recurrence and survival in patients with early stage LMS, as
listed in Table 5. Morcellation of LMS during endoscopic surgeries
or laparotomy could cause dissemination of LMS tumors, increase
local pelvic tumor recurrence, and affect patient survival out-
come.7e11 However, tumor recurrence and survival could also
remain unaffected by tumor morcellation.12 Our study demon-
strated that morcellation is not an independent factor affecting
patient survival in stage 1 LMS. Size of LMS is the major factor
predicting DFS and OS in early LMS.0.00
0.25
0.5
0.75
1.00
0 50 100 150 200 250
mo
Nonmorcellation group
Morcellation group
p = 0.99
D
ise ase -free survival
Figure 1. Disease-free survival relative to tumor morcellation in patients with stage 1
leiomyosarcoma.Multiple factors could inﬂuence the surgical outcome of LMS
patients.10 Prognosis of LMS is less predictable. Tumor stage is the
most important prognostic factor for LMS, but recurrence and
metastasis occur frequently in early stage LMS.13 The recurrence
rate in early stage LMS was reported to be 16% in the 1st year and as
high as 76% among the surviving patients at 10 years after opera-
tion.14 This high recurrence rate in LMS causes poor prognosis in
early stage disease. The 5-year OS of early stage LMS was reported
in the range of 39e77%15,16 (Table 5, Figure 3).
To provide more accurate prognostic information for patients
with LMS conﬁned to the uterus and/or cervix regions, stage 1 LMS
was subdivided into 1a (tumor size < 5 cm) and 1b (tumor
size > 5 cm) in the 2009 FIGO staging classiﬁcation. However, pa-
tient survival could be further correlated with tumor size beyond
5 cm. The 5-year survival rates of patients with 5 cm, 5e10 cm, and
10 cm LMSwere reported as 76.6%, 52.9%, and 41.9%, respectively, in
a population-based study of 819 patients.16 In another Norwegian
series involving 193 patients with stage 1 LMS, the corresponding
rates were 64.0%, 56.4%, and 29.3%.13 A tumor size cutoff value of
10 cm could be used as a signiﬁcant independent poor prognostic
factor with a relative hazard of 2.7 for LMS.13 In our study, we found
tumor size to be an independent prognostic factor to predict OS and
DFS in early stage LMS patients. Tumors in our patients were bigger
compared with many studies, which can be seen in the data pre-
sented in Table 5. Although there was no difference in tumor size
among our two groups of patients, more patients in the non-
morcellation group had a tumor size > 10 cm compared with those
in the morcellation group (18 patients, 62.1% vs. 2 patients, 1.4%,
p < 0.005). Patients with tumor recurrence showed signiﬁcantly
larger tumor size than patients without tumor recurrence in the
nonmorcellation group (subtotal/total abdominal hysterectomy;
Table 4). The greater tumor size in the nonmorcellation group could
cause a higher recurrence rate and lower survival rate compared
with the literature report8 (Figure 3). Being a tertiary university
hospital, we were more likely to receive referred cases with huge
tumors. This could cause a selection bias in our study. We adjusted
this bias using Cox regression analysis. However, a better alterna-
tive method is to construct a randomized study, which is impos-
sible due to the limitation of performing minimally invasive
surgery in huge tumors.
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Figure 2. Overall survival relative to tumor morcellation in patients with stage 1
leiomyosarcoma.
Table 5
Literature reports on clinical manifestation and outcome in patients with early stage LM
Study FIGO stage a Case no. Tumor s
Nonmorcellation
Gadducci et al 198915 1e2 23 NS
Major et al 199318 1e2 59 (8 upstaged after operation) NS
Gadducci et al 199622 1e2 90 NS
Abeler et al 200913 1 193 NS
Pelmus et al 200914 1e2 72 7 (2e23)
Zivanovic et al 200924 1 119 NS
Raut et al 200925 1 110 NS
Garg et al 201016 1 1a: 158 1a: 3.5
1b: 661 1b: 11.0
Ricci et al 201320 1e2 108 9.4
Giuntoli et al 201326 1 Stage 1a: 29 NS
Stage 1b: 128
Rauh-Hain et al 201317 1e2 Stage 1: 92 NS
Stage 2: 7
Mancari et al 201421 1e2 140 NS
Morcellation
Einstein et al 200819 1 5 (1 upstaged after postoperative
image, 2 upstaged at reoperation)
NS
Oduyebo et al 201411 1 15 (2 upstaged after postoperative
image, 2 upstaged at reoperation)
NS
Nonmorcellation vs. morcellation
Morice et al 200312 NS 89 vs. 34 NS
Perri et al 20097 1 21 vs. 16 NS
Park et al 20118 1e2 31 vs. 25 9.8 vs. 7
George et al 20149 1 39 vs. 19 NS
This study 1 29 vs. 14 11.6 vs.
AWD¼ alive with disease; DFS ¼ disease-free survival; FIGO¼ International Federation o
NS ¼ not speciﬁed; OS ¼ overall survival; PFS ¼ progression-free survival.
a Stage 1e2 based on the 1988 FIGO staging classiﬁcation system.
K.-H. Lin et al. / Gynecology and Minimally Invasive Therapy 4 (2015) 81e8684Mitotic count was also an independent prognostic factor for
LMS. In LMS stages 1 and 2, mitotic index with 10/10 high-power
ﬁeld as cutoff had a relative hazard of 1.9 in multivariate anal-
ysis.13 However, in a 10-year study of 167 LMS cases, mitotic count
was found to be associated with survival only at the late stage.17 In
our study, mitotic count was not obtained in nine (20.9%) cases.
Although mitotic count was not associated with patient survival in
this study, this could limit a full interpretation of our results.
Another limitation of our study is the very small sample size
included. In addition, only 11 (25.6%) of our cases received com-
plete staging at initial surgery or at reoperation. In a series of 59
cases with early stage LMS, complete staging surgery revealed 3.5%
lymph node metastases, 3.5% adnexal metastases, 5.3% positive
peritoneal cytology, and eight (13.6%) patients were upstaged.18 In
most studies, restaging surgeries after morcellation were either
performed in selected cases8,11,19 or not performed.9 One study
reported restaging in ﬁve of 25 cases after morcellation and noneS with or without morcellation.
ize, cm Recurrence, n/N (%) Recurrence at
locoregional sites
Survival, %
12 (52) 4 (17) 54, 2 y
39, 5 y
42 (71) 8 (14) DFS: 31, 3 y
35 (39), median 16 mo 5 (6) OS: 58, 5 y
NS NS OS: 51, 5 y
11/69 (16), 1 y
30/65 (46), 3 y
33/58 (57), 5 y
38/50 (76), 10 y
38 (53), median 68 mo
5/64 (8), 1 y
16/53 (30), 3 y
21/46 (46), 5 y
24/32 (75), 10 y
24 (33), median
68 mo
OS: 57, 5 y
OS: 42, 10 y
NS NS OS: 57, 5 y
NS NS Median DFS: 24.9 mo
Median OS: 69.2 mo
NS NS OS: stage 1a: 76.6, 5 y
stage 1b: 48.4, 5 y
74 (69), median 41.8 mo 21 (19) Median OS: 52.6 mo
NS NS Median survival
1a: >20 y; 1b: 5.3 y
52 (52) 24 (24) Median OS:
75 mo (stage 1)
66 mo (stage 2)
87 (62), median 63 mo 24 (17) DFS: 43, 5 y
OS: 64, 5 y
NS NS 3 NED & 2 AWD;
median: 31 mo
8/13 (62) 7/13 (54) Median DFS: 6.3 mo
(recurrent cases)
Median OS: 23.4 mo
(nonrecurrent cases)
3/79 (4) vs. 3/31 (9.6)
at 3 mo
10% vs. 10% at 6 mo
Similar
NS vs. 10 (63)
Median: 72 mo vs. 24 mo
NS Alive, n (%):
13 (62) vs. 6 (38)
.3 7 (23) vs. 13 (52)
Median: 31 mo vs. 27 mo
Mean: 63 mo vs. 39 mo
4 (13) vs. 11 (44) OS: 73 vs. 46, 5 y
DFS: 65 vs. 40, 5 y
20 (51) vs. 14 (74) 6 (15) vs. 12 (63) OS: 73 vs. 64, 3 y
Median PFS: 39.6
mo vs. 10.8 mo
Median OS: NS vs.
48 mo
7.3 14 (48) vs. 8 (57) 4 (14) vs. 3 (21) OS: 52 vs. 34, 3 y
Median: 20 mo vs. 24 mo OS: 34 vs. 34, 5 y
Mean: 55 mo vs. 33 mo Median OS: 43 mo
vs. 35 mo
f Gynecology and Obstetrics; LMS ¼ leiomyosarcoma; NED ¼ no evidence of disease,
Follow-up (y)
0 2 4 6 8 10
%
0
20
40
60
80
100
Figure 3. Overall survival rates in patients with early stage nonmorcellated leiomyo-
sarcoma according to literature reports listed in Table 5. Open circles represent stage 1
to 2; open squares indicate stage 1; ﬁlled square indicates stage 1a; ﬁlled circles
indicate stage 1b.
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two of seven patients, respectively, were upstaged in restaging
surgeries after morcellation.11,19 Patients who were upstaged were
reoperated at > 1 month after the initial morcellation surgery.11,19
Delayed reoperation after initial morcellation might be an impor-
tant factor causing upstaging. One patient in the nonmorcellation
group received staging surgery 16 days after the initial surgery and
six patients with initial myomectomy in the morcellation group
received hysterectomy at an average period of 18.5 days after the
initial surgery. None of our patients were upstaged.
The recurrence rate for early stage LMS increased steadily with
time after treatment.14 At 5 years after surgery, more than 50% of
patients were reported to experience recurrence14,15,17,20,21
(Table 5). A majority of ﬁrst recurrences occur in the extra-pelvic
region, and the lung is the most common site of recurrence.17,20
The recurrence rate in the pelvic cavity is less frequent and re-
ported in the range of 6e19% at median follow-up periods of 16e42
months20,22 (Table 2). However, pelvic recurrence rate among the
survived patients at 10 years after the operation was reported to be
75%.14 Patients with morcellation during pelvic surgery were found
to have more tumor recurrence than patients without
morcellation.7e9 The pelvic recurrence rate was 44% at a median
follow-up period of 27 months in patients with morcellation.8 In
addition, pelvic recurrence was a dominant site of tumor recur-
rence after morcellation.8,9 Our study did not ﬁnd higher tumor
recurrence or pelvic recurrence rates in patients with morcellation
compared with patients without morcellation. Similarly, in a study
composed of 89 patients withoutmorcellation and 34 patients with
morcellation, pelvic recurrence rate was reported to be 10% at 6
months after the operation irrespective of the use of morcellation.12
We performed laparoscopic myomectomy through the technique of
in situ morcellation,23 which might entrap myomatous mass in the
uterine cavity and restrict it from pelvic spreading during morcel-
lation. Recurrence did not occur in our two cases that received
laparoscopic myomectomy. Careful and gentle use of morcellation
could explain why morcellation did not increase tumor recurrence
nor affect patient survivals in our study. However, more cases are
needed to conﬁrm this observation.Most of our patients received adjuvant therapy after the opera-
tion. Adjuvant therapiesweremore frequently used inpatients after
morcellation compared with patients without morcellation.
Radiotherapy was the predominate type of adjuvant therapy.
Radiotherapy after surgery could decrease local recurrence in early
staged LMS.20 However, the beneﬁts of adjuvant therapy on survival
outcome after surgery such as radiotherapy or chemotherapy were
inconsistent.17 More adjuvant therapies were prescribed in patients
after morcellation compared with nonmorcellation patients. Adju-
vant therapies were performed in 46.1% versus 26.3%, and 61.3%
versus 56%, inpatientswithmorcellation versusnonmorcellation, in
two studies.8,9 Chemotherapy was the more commonly selected
adjuvant therapy aftermorcellation.8,9 No deﬁnite report was found
related to tumor recurrence and adjuvant therapies in early LMS.
In conclusion, our study demonstrated that several factors could
affect patient survivals in early stage LMS. Among these factors, we
found tumor size as the major factor inﬂuencing patient survivals.
Morcellation apparently is not associated with aworse prognosis in
early stage LMS. However, more cases and more studies are needed
to make a deﬁnite conclusion. At present, caution should still be
exercised while using intraperitoneal morcellation.References
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